Psoriasis

Psoriasis mangrupikeun panyakit otoimun anu tahan panjang, henteu tepa anu dicirikeun ku daérah kulit anu teu normal. Wewengkon ieu beureum, atawa wungu dina sababaraha urang jeung kulit darker, garing, gatal (itchy), sarta berlapis sisik (scaly). Tatu kana kulit bisa memicu parobahan kulit psoriatik di titik éta, nu katelah "fenomena Koebner (Koebner phenomenon)".

Rupa-rupa pangobatan tiasa ngabantosan ngontrol gejala. Pangobatan ieu kalebet krim stéroid, krim vitamin D3, sinar ultraviolét, sareng obat imunosupresif, sapertos methotrexate. Ngeunaan 75% tina involvement kulit ningkat kalawan krim (creams) nyalira. Rupa-rupa agén imunologis biologis dikembangkeun pikeun pengobatan psoriasis.

Psoriasis mangrupikeun gangguan umum sareng panyakit mangaruhan 2-4% tina populasi. Lalaki sareng awéwé kapangaruhan ku frékuénsi anu sami. Kasakit bisa dimimitian dina sagala umur, tapi ilaharna dimimitian dina dewasa. artritis psoriatik (Psoriatic arthritis) mangaruhan nepi ka 30% jalma kalawan psoriasis.

○ Perlakuan - Narkoba OTC
Cahya panonpoé bisa mantuan psoriasis sabab paparan panonpoé induces parobahan immunological di penderita psoriasis. Salep hydrocortisone hampang tiasa ngabantosan pikeun ngubaran sababaraha lesi leutik psoriasis.
#OTC salep steroid (steroid ointment)

○ Perlakuan
Psoriasis mangrupikeun panyakit kronis sareng seueur agén pangobatan anu ditaliti. Biologis anu paling efektif tapi mahal pisan.
#salep steroid poténsi tinggi (High potency steroid ointment)
#krim calcipotriol (Calcipotriol cream)
#Fototerapi (Phototherapy)
#Biologics (e.g. infliximab, adalimumab, secukinumab, ustekinumab)

Inpo leuwih ― Urang sundan

Deui jeung leungeun hiji jalma kalawan psoriasis
psoriasis has
Guttate Psoriasis; Ieu sering lumangsung sanggeus gejala tiis.
Guttate Psoriasis

Plak sisik kandel sareng erythema mangrupikeun manifestasi khas psoriasis.
Psoriasis dina palem. Upami éta lumangsung dina dampal leungeun, bisul tiasa ngabentuk.
Parah 'psoriasis pustular'.
Guttate Psoriasis

Pilarian gambar

References

Psoriasis 28846344

NIH

Phototherapy 33085287

NIH

Tumor Necrosis Factor Inhibitors 29494032

NIH

Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).